Form 4: Cingulate EVP Granted 7,334 Stock Options

Cingulate Inc.'s Executive Vice President and Chief Scientific Officer, Raul R. Silva, was granted 7,334 stock options with an exercise price of $3.92 per share.

Summary

• Raul R. Silva, EVP and CSO of Cingulate Inc. (CING), was granted 7,334 stock options.
• The options have an exercise price of $3.92 per share.
• The transaction date for the grant was September 30, 2025.
• The options become exercisable on September 30, 2025, and expire on September 30, 2035.
• Each option represents the right to buy one share of Cingulate Inc. common stock.
• The grant was made pursuant to the terms of Dr. Silva's amended Employment Agreement.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is a standard practice aimed at aligning management incentives with shareholder value creation and executive retention. It is a neutral to slightly positive event, indicating continued commitment to executive compensation strategies.

Positives

• The stock option grant aligns the executive's financial interests with those of the shareholders, incentivizing long-term company performance.
• It serves as a retention mechanism for a key executive, Dr. Raul R. Silva, EVP and CSO.

Negatives

• Potential for future dilution of existing shareholders if the options are exercised, though the number of shares is relatively small.

Future Outlook

This filing does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the future exercisability and expiration of the options.

Industry Context

The grant of stock options to key executives is a common practice across various industries, particularly in biotechnology and pharmaceutical sectors like Cingulate Inc., to incentivize performance and retain talent.

Comparison to Industry Standards

• Executive compensation packages, including stock option grants, are standard practice in the pharmaceutical and biotech industries. The size of this grant for an EVP and CSO is within typical ranges for a company of Cingulate's stage, aiming to align executive incentives with long-term shareholder value.
• Comparable companies often use similar equity-based compensation structures to attract and retain high-caliber scientific and executive talent, linking their rewards to the company's stock performance.

Related Party Transactions

• The grant of stock options to Raul R. Silva, an EVP and CSO, constitutes a related party transaction as it involves compensation from the company to a key executive.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also benefits from increased alignment of executive interests with long-term stock performance.
• Employees: Reinforces the company's commitment to equity-based compensation for key personnel.

Key Dates

Recommendation

This Form 4 reports a routine stock option grant to an executive, which is a standard component of compensation. It does not provide sufficient new information to alter an investment thesis or significantly impact the company's fundamentals, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Cingulate Inc., CING, stock option, executive compensation, insider transaction, Form 4, Raul Silva, equity grant